Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CANN GROUP LIMITED AGM Information 2023

Aug 28, 2023

64603_rns_2023-08-28_950cd6ba-1829-46dd-9b81-fbf6db820977.pdf

AGM Information

Open in viewer

Opens in your device viewer

==> picture [109 x 42] intentionally omitted <==

ASX ANNOUNCEMENT

29 August 2023

Notice of date of AGM and other relevant dates

29 August 2023 – Pursuant to ASX Listing Rule 3.13.1, Cann Group Limited (ASX: CAN) ( Cann or the Company ) is pleased to advise the following details in relation to the Company’s forthcoming Annual General Meeting ( AGM ):

Thursday, 26 October 2023 Date & time for AGM at 10.00am (Melbourne time) Date of Notice of Meeting dispatch Thursday, 21 September 2023 Last date for receipt of nominations as a director Thursday, 7 September 2023

Further details in relation to the AGM, including items of business to be voted upon by shareholders, and instructions on how shareholders may attend and vote at the meeting, will be provided in the Notice of Meeting.

The Company's Appendix 4E, together with the FY 2023 Annual Report were released to the ASX on 28 August 2023 and can be accessed and downloaded from the Company’s website here.

Shareholders may obtain a hard copy of the Annual Report by emailing a request to the Company at [email protected].

The Company looks forward to shareholders participating at this year’s AGM.

Authorised for release by Deborah Ambrosini, Company Secretary, Cann Group Limited.

For all media enquiries please contact:

Jackson Paine Corporate Communications Manager +61 439 492 955 [email protected]

For all other information please contact:

Peter Koetsier Deborah Ambrosini CEO CFO and Company Secretary Cann Group Limited Cann Group Limited +61 3 9095 7088 +61 3 9095 7088 [email protected] [email protected]

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is enhancing patients’ lives by developing, producing, and supplying innovative cannabis medicines. The Company has research facilities and corporate headquarters in Melbourne and operates a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

Learn more at: www.canngrouplimited.com | www.satipharm.com

Cann Group Limited (ACN 603 949 739) 262-276 Lorimer Street, Port Melbourne, VIC 3207 Australia Ph: +61 3 9095 7088